Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: Therapeutic implications Journal Article
| Authors: | Kukreja, A.; Hutchinson, A.; Mazumder, A.; Vesole, D.; Angitapalli, R.; Jagannath, S.; O'Connor, O. A.; Dhodapkar, M. V. |
| Article Title: | Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: Therapeutic implications |
| Abstract: | Recent studies have shown that the interactions between tumour and dendritic cells (DCs) promote clonogenic growth of lymphoproliferative tumours, particularly myeloma. The present study showed that the proteasome inhibitor, bortezomib, disrupts this interaction. Targeting the drug to DCs was required for optimal suppression of tumour growth, including primary myeloma tumour progenitors in clonogenic assays. Bortezomib lead to dose-dependent induction of apoptosis in both myeloid and plasmacytoid DCs, and the sensitivity of DCs to bortezomib was comparable with that of tumour cells. These data suggest that disruption of tumour-DC interactions may contribute to the clinical effects of bortezomib. © 2007 The Authors. |
| Keywords: | controlled study; human cell; dose response; drug targeting; flow cytometry; apoptosis; bortezomib; multiple myeloma; boronic acids; protease inhibitors; pyrazines; dendritic cell; tumor cells, cultured; cell line, tumor; dendritic cells; lymphoma; tumor growth; colony-forming units assay; cell interaction; cell communication; myeloma; clonogenesis; plasmacytoid dendritic cells; myeloid dendritic cells; tumour microenvironment |
| Journal Title: | British Journal of Haematology |
| Volume: | 136 |
| Issue: | 1 |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2007-01-01 |
| Start Page: | 106 |
| End Page: | 110 |
| Language: | English |
| DOI: | 10.1111/j.1365-2141.2006.06369.x |
| PUBMED: | 17222199 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 23" - "Export Date: 17 November 2011" - "CODEN: BJHEA" - "Source: Scopus" |
